Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

Joseph R LuttDivision of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USAAbstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades. Further understanding of the pathophysiology of the diseas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Joseph R Lutt
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/5e9983f24c4644b3983ed12b20b35e50
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e9983f24c4644b3983ed12b20b35e50
record_format	dspace
spelling	oai:doaj.org-article:5e9983f24c4644b3983ed12b20b35e502021-12-02T01:10:37ZEfficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis1179-156Xhttps://doaj.org/article/5e9983f24c4644b3983ed12b20b35e502009-05-01T00:00:00Zhttp://www.dovepress.com/efficacy-safety-and-tolerability-of-abatacept-in-the-management-of-rhe-a3115https://doaj.org/toc/1179-156XJoseph R LuttDivision of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USAAbstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades. Further understanding of the pathophysiology of the disease process has resulted in the development of biologic agents that target proinflammatory cytokines and both B and T lymphocytes. By blocking an important costimulatory pathway, abatacept leads to a dramatic reduction in T cell stimulation and proliferation. Multiple clinical trials have revealed consistent benefit with regards to clinical and radiographic efficacy, quality of life, and disability in patients suffering from RA who have had inadequate responses to methotrexate or tumor necrosis factor inhibitors. The possibility of remission when used early in the disease course has also been demonstrated. Importantly, abatacept has been very well tolerated with a low rate of serious infections and no apparent increase in malignancies to date. Continued surveillance of the benefits and risks will help to better define its place amongst the other biologic agents in the treatment of RA.Keywords: abatacept, rheumatoid arthritis, infliximab, etanercept, adalimumab, rituximab, disease-modifying antirheumatic drug Joseph R LuttDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2009, Iss default, Pp 17-35 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Joseph R Lutt Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
description	Joseph R LuttDivision of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USAAbstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades. Further understanding of the pathophysiology of the disease process has resulted in the development of biologic agents that target proinflammatory cytokines and both B and T lymphocytes. By blocking an important costimulatory pathway, abatacept leads to a dramatic reduction in T cell stimulation and proliferation. Multiple clinical trials have revealed consistent benefit with regards to clinical and radiographic efficacy, quality of life, and disability in patients suffering from RA who have had inadequate responses to methotrexate or tumor necrosis factor inhibitors. The possibility of remission when used early in the disease course has also been demonstrated. Importantly, abatacept has been very well tolerated with a low rate of serious infections and no apparent increase in malignancies to date. Continued surveillance of the benefits and risks will help to better define its place amongst the other biologic agents in the treatment of RA.Keywords: abatacept, rheumatoid arthritis, infliximab, etanercept, adalimumab, rituximab, disease-modifying antirheumatic drug
format	article
author	Joseph R Lutt
author_facet	Joseph R Lutt
author_sort	Joseph R Lutt
title	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
title_short	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
title_full	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
title_fullStr	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
title_full_unstemmed	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
title_sort	efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/5e9983f24c4644b3983ed12b20b35e50
work_keys_str_mv	AT josephrlutt efficacysafetyandtolerabilityofabataceptinthemanagementofrheumatoidarthritis
_version_	1718403258035208192

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

Ejemplares similares